Plain-English translation of NCT05394922 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying how the structure of certain antibodies in lupus patients' blood changes as the disease gets better or worse. By analyzing blood samples from 140 people with lupus, they hope to identify a simple way to predict disease flares and track how well treatment is working.
Lupus can be unpredictable and hard to monitor with current tests. This study aims to find a new blood marker that could help doctors catch disease flares earlier and adjust treatment before serious complications happen.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital at the start of the study and again after one year to have blood drawn. If you experience a lupus flare at any point during the year, you would also provide a blood sample at that time. The blood samples are processed and stored for analysis after the study ends. The entire participation lasts about one year, with minimal time commitment beyond the blood draws.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
France
Enrollment target
~140 participants
Started
August 2022
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Thierry VINCENT, MD
University Hospital, Montpellier
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.